Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.63 |
| ▸ | CNR1 | P21554 | 7/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385288 | 0.85 | GABRA5 (0.44) | CNR2CNR1GABRA5GABRA1TRPA1 | |
| SCHEMBL3927687 | 0.84 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL3925492 | 0.83 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL4387679 | 0.82 | CNR2 (0.67) | CNR2CNR1GABRA5GABRA1 | |
| SCHEMBL3916163 | 0.81 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL3994951 | 0.81 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL3916320 | 0.81 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL3919062 | 0.81 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL4377147 | 0.80 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL3927668 | 0.80 | CNR2 (0.64) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | claimed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885GABRA5 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.